UMMS, RXi Researcher Wins $5M NIH Grant to Develop Oral RNAi Delivery Tech

While the funding will directly benefit UMMS researcher Michael Czech, it is also expected to be a boon for RXi Pharmaceuticals, which Czech co-founded, since the company holds an exclusive license to the delivery technology for therapeutic RNAi applications.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.